Your browser doesn't support javascript.
loading
COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity.
Kroemer, Marie; Spehner, Laurie; Vettoretti, Lucie; Bouard, Adeline; Eberst, Guillaume; Pili Floury, Sebastien; Capellier, Gilles; Lepiller, Quentin; Orillard, Emeline; Mansi, Laura; Clairet, Anne-Laure; Westeel, Virginie; Limat, Samuel; Dubois, Maxime; Malinowski, Léa; Bohard, Louis; Borg, Christophe; Chirouze, Catherine; Bouiller, Kevin.
Afiliación
  • Kroemer M; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, F-25000 Besançon, France; Department of Pharmacy, University Hospital of Besançon, F-25000 Besançon, France; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactio
  • Spehner L; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, F-25000 Besançon, France; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France;
  • Vettoretti L; Anesthesia and Intensive Care Unit, University Hospital of Besançon, F-25000 Besançon, France; Medical Intensive Care Unit, University Hospital of Besançon, F-25000 Besançon, France.
  • Bouard A; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, F-25000 Besançon, France.
  • Eberst G; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Chest Disease, University Hospital of Besançon, F-25000 Besançon, France.
  • Pili Floury S; Anesthesia and Intensive Care Unit, University Hospital of Besançon, F-25000 Besançon, France; Research Unit EA3920, Université de Franche Comté, F-25000 Besançon, France.
  • Capellier G; Medical Intensive Care Unit, University Hospital of Besançon, F-25000 Besançon, France; Research Unit EA3920, Université de Franche Comté, F-25000 Besançon, France; Australian and New Zealand Intensive Care Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Austr
  • Lepiller Q; Department of Virology, University Hospital of Besançon, F-25000 Besançon, France; Research Unit EA3181, Université de Franche Comté, F-25000 Besançon, France.
  • Orillard E; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, University Hospital of Besançon, F-25000 Besançon, France.
  • Mansi L; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, University Hospital of Besançon, F-25000 Besançon, France.
  • Clairet AL; Department of Pharmacy, University Hospital of Besançon, F-25000 Besançon, France.
  • Westeel V; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Chest Disease, University Hospital of Besançon, F-25000 Besançon, France.
  • Limat S; Department of Pharmacy, University Hospital of Besançon, F-25000 Besançon, France; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
  • Dubois M; Department of Pharmacy, University Hospital of Besançon, F-25000 Besançon, France.
  • Malinowski L; Department of Infectious Disease, University Hospital of Besançon, F-25000 Besançon, France.
  • Bohard L; Department of Infectious Disease, University Hospital of Besançon, F-25000 Besançon, France.
  • Borg C; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, F-25000 Besançon, France; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France;
  • Chirouze C; Department of Infectious Disease, University Hospital of Besançon, F-25000 Besançon, France; UMR-CNRS 6249 Chrono-Environnement, Université Bourgogne Franche-Comté, F-25000 Besançon, France.
  • Bouiller K; Department of Infectious Disease, University Hospital of Besançon, F-25000 Besançon, France; UMR-CNRS 6249 Chrono-Environnement, Université Bourgogne Franche-Comté, F-25000 Besançon, France. Electronic address: kbouiller@chu-besancon.fr.
J Infect ; 82(2): 282-327, 2021 02.
Article en En | MEDLINE | ID: mdl-32853599
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Observational_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: J Infect Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Observational_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: J Infect Año: 2021 Tipo del documento: Article